What is a gray-market peptide and why does PeRx avoid them?

Gray-market peptides are substances sold by research-chemical vendors and some wellness sellers, usually labeled "not for human use" or "research use only," with no licensed pharmacy in the supply chain. Reporting and regulators have documented that this material can carry contaminants such as bacteria and heavy metals, and that peptides are chemically unstable and can degrade if stored or handled improperly. With no pharmacy-grade source, there is no certificate of analysis tying a specific vial to verified identity, purity, and sterility. PeRx only prescribes peptides that can be compounded by a licensed pharmacy against a patient-specific prescription, so a gray-market-only peptide is one we simply cannot offer responsibly.

If a peptide is trending online, why might PeRx still not offer it?

Popularity is not a medical indication. Some of the most-discussed peptides online are popular because they are marketed aggressively, not because they solve a problem a provider could name. A vivid mechanism or a viral before-and-after is not the same as a legitimate clinical use. We let the clinical question decide what goes on the catalog, not search trends. A peptide moving onto our catalog later, if a real use case and a safe supply emerge, is always possible. Offering it on hype alone is not.

Does PeRx decline some peptides over safety concerns?

Yes. Separate from sourcing, we decline peptides that carry a documented safety risk that outweighs the benefit. This is not about a substance simply being understudied. It is about a known, serious signal of harm, such as a peptide linked to significant adverse events, one prone to contamination, or one whose interactions make it genuinely hazardous. When the demonstrated downside is larger than any benefit we could honestly claim, we leave it off the catalog.

What does it mean that PeRx declines certain peptides "on purpose"?

It means the boundary is a standard we apply, not an accident of inventory. Every request runs against the same questions: is there a pharmacy-grade source, is there a legitimate medical use behind it, and does the benefit outweigh any documented risk. If the answer to any of those is no, we decline, even when there is demand. That consistency is the point. A practice that says yes to everything is not really evaluating anything.

All blogsPeptide Guide

Why We Don't Prescribe Certain Peptides (And What That Tells You About Us)

Any clinic can publish the list of what it sells. The more honest signal is the list of what it refuses to. PeRx declines whole categories of peptides on purpose: the ones with no pharmacy-grade source, the ones sold on hype with no real medical use, and the ones whose documented risk outweighs the benefit. Here is the reasoning behind each line we will not cross.

PeRx Peptides11 min readUpdated June 23, 2026

What a clinic refuses to prescribe reveals its standards more clearly than what it stocks.

In this article

Key Takeaways

What a clinic refuses to sell is a clearer signal of its standards than what it stocks. PeRx declines whole categories of peptides on purpose, and the reasoning is the point of this article.
We will not prescribe peptides that exist only on the gray market with no pharmacy-grade source. Without a licensed pharmacy and a certificate of analysis, there is no verified identity, purity, or sterility behind the vial.
We decline peptides sold on marketing hype with no genuine medical use behind them. A vivid mechanism or a viral testimonial is not a clinical indication.
We decline peptides whose documented safety risk outweighs any benefit we could honestly claim. A known, serious harm signal is a reason to say no, even when demand is high.

What We Refuse Tells You More Than What We Sell

The thesis, stated plainly

Every peptide clinic publishes a menu. The menu is marketing. The harder, more honest document is the list of peptides a clinic has decided it will not prescribe, and why. We keep that list on purpose. It is shaped by three lines we will not cross: no pharmacy-grade source, no legitimate medical use behind the hype, and a documented risk that outweighs the benefit. None of those is about a lack of demand. Each one is a standard we chose. Read the reasoning and you will know more about how we practice than any product page could tell you.

This is a companion to what providers review before prescribing peptides. That guide is about the checklist a provider runs on an individual request. This one sits a level above it, at the catalog. Before a single intake is ever reviewed, a peptide has to clear a threshold to be on offer at all. Plenty of substances people ask us about do not clear it, and we would rather explain that than quietly leave them off a list and hope no one notices.

Reason 1: No Pharmacy-Grade Source

The first and most common reason we decline a peptide is that there is no legitimate way to source it. PeRx only prescribes peptides that a licensed compounding pharmacy will prepare against a patient-specific prescription. If the only supply for a given peptide is the gray market, then there is nothing for us to prescribe, no matter how interesting the molecule is.

The gray market is real and large. Investigative reporting has described how wellness spas, multilevel marketers, and telehealth sites sell vials of "research grade" peptides labeled "not for human use," a label that lets a vendor sell the material while disclaiming the obvious use. The problem is not the label. It is that with no pharmacy in the chain, nothing verifies what is in the vial. ProPublica’s reporting noted that the manufacturing process can introduce impurities including bacteria and heavy metals, and that peptides are chemically unstable and can change composition if stored at the wrong temperature or handled roughly, which raises contamination risk or simply renders the product inert.

Bedell J. "An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs." ProPublica (2025): documents gray-market "research grade" peptides labeled "not for human use," and the risk of impurities including bacteria and heavy metals plus instability from improper handling. View study

A pharmacy-grade source is what closes that gap. A licensed pharmacy works from a verified active ingredient and issues a certificate of analysis confirming the vial’s identity, purity, and sterility. That document is the difference between a medication and a chemistry experiment, and it is exactly what a gray-market peptide cannot produce. If you want the detail on reading one, our guide on how to read a peptide COA walks through it. The short version: when a peptide has no pharmacy-grade source, declining it is not caution, it is the only responsible option.

What backs the vial	A peptide we can offer	A peptide we decline
Supply chain	Licensed compounding pharmacy preparing a patient-specific prescription.	Research-chemical vendor or wellness seller, no pharmacy in the chain.
Documentation	Certificate of analysis verifying identity, purity, and sterility for the batch.	A "not for human use" label and, at best, a vendor’s own unverifiable claims.
Accountability	A named, licensed provider and pharmacy stand behind the prescription.	No prescriber, no medical record, no one accountable if something is wrong.

Reason 2: No Legitimate Medical Use, Just Hype

The second reason has nothing to do with sourcing and everything to do with whether there is a real reason to use the peptide at all. A molecule can be perfectly sourceable and still be sold on nothing but marketing. A vivid mechanism, a viral before-and-after, an influencer protocol: none of those is a medical indication. When a peptide is popular only because it is being marketed well, and there is no genuine problem it is meant to address, there is nothing for a provider to actually be treating or supporting. We decline those.

It is worth being precise here, because this is not the same as turning away anything new. Plenty of legitimate peptides are early in their human research and we are comfortable offering them, because there is a defensible clinical rationale behind them and a definable job they do. The line is not how many trials a peptide has. It is whether the peptide answers a real need or simply rides a trend. A therapy with a genuine use case and maturing evidence is a candidate. A peptide that exists mainly to be sold is not, no matter how much demand the marketing has manufactured. For the basics of what peptide therapy is actually for, see what is peptide therapy.

A trend is not an indication

Some of the most-searched peptides online are popular precisely because they are marketed aggressively, not because they solve a problem a provider could name. We let the clinical question decide what goes on the catalog, not the search volume. If the only honest answer to "what is this for" is "it is trending," that is a reason to decline it, not a reason to stock it.

Reason 3: The Documented Risk Outweighs the Benefit

The third reason applies even to peptides that can be sourced and have a plausible use. Sometimes the problem is that the known risk is real and the upside does not justify it. This is a different judgment from "we do not have much data yet." Here the concern is not silence in the literature, it is a documented signal of harm: peptides linked to serious adverse events, ones prone to contamination, or ones whose interactions make them genuinely hazardous. When the demonstrated downside is larger than any benefit we could honestly claim, we decline.

Documented harm, not a hypothetical

This is not an abstract worry. In ProPublica’s reporting on peptide safety, study subjects exposed to several injectable peptides experienced adverse events, including death, though causality was not definitively established in every case. Injectable peptides also carry a real risk of immune reactions, ranging from minor to, rarely, anaphylaxis. None of that makes peptides dangerous as a class. It means that when a specific peptide carries a known, serious safety signal, the responsible move is to weigh that honestly against the benefit, and to decline when the risk wins.

Bedell J. "An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs." ProPublica (2025): reports that subjects exposed to several injectable peptides experienced adverse events including death (causality not definitively established), and that injectable peptides carry immune-reaction risk up to anaphylaxis. View study

Regulators make a version of this same call. When the FDA evaluates substances nominated for compounding under Section 503A, it has placed some into a category specifically because significant safety risks were identified with their use. We are not the FDA, and the regulatory picture for peptides has been a shifting gray zone through 2025 and 2026. But the underlying logic we borrow is simple: a documented safety risk that outweighs the benefit is a reason to keep a substance off the catalog, not a detail to gloss over.

U.S. Food & Drug Administration. "Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks" and the Section 503A bulk-substances framework: the agency has placed substances into a category because significant safety risks were identified with their use in compounding. View study

What This Restraint Signals About Quality

Put the three reasons together and a pattern shows up. We decline peptides with no pharmacy-grade source, peptides that exist on hype with no real medical use, and peptides whose documented risk outweighs any benefit we could honestly claim. Every one of those is a place where saying yes would have been easier and more profitable. We said no on purpose. That is the signal worth reading.

We offer a peptide when...	We decline a peptide when...	What the choice signals
Sourcing	A licensed pharmacy can compound it with a verifying certificate of analysis.	The only supply is gray-market material with no pharmacy and no verification.	We will not put our name on a vial nobody can vouch for.
Legitimate use	There is a real clinical problem it is meant to address.	It is sold on marketing with no genuine medical use behind it.	We stock what does a definable job, not what is trending.
Risk and benefit	The benefit clearly outweighs a well-characterized, manageable risk.	There is a documented safety signal the upside does not justify.	We weigh known harm honestly, even against real demand.

A useful test for any peptide service: ask what it will not prescribe, and why. If the answer is "we offer everything," that is not breadth, it is the absence of a standard. The clinics worth trusting are the ones that can name their lines and defend them. We just did. When you are ready to see the result of applying these standards, the peptides we do offer are what is left after the list above is removed.

Frequently Asked Questions

For one of a few concrete reasons: there is no pharmacy-grade source, so the only supply is gray-market material of unknown purity; there is no legitimate medical use behind it, only marketing; or it carries a documented safety risk that outweighs the benefit. At PeRx these are category decisions applied consistently, not improvised case by case.

A gray-market peptide is a substance sold by research-chemical vendors or some wellness sellers, usually labeled "not for human use" or "research use only," with no licensed pharmacy in the supply chain. Reporting and regulators have documented that this material can carry contaminants such as bacteria and heavy metals, and that peptides can degrade if stored or handled improperly. With no pharmacy-grade source, there is no certificate of analysis verifying identity, purity, and sterility.

Popularity is not a medical indication. Some of the most-discussed peptides online are popular because they are marketed aggressively, not because they solve a problem a provider could name. A vivid mechanism or a viral before-and-after is not a legitimate clinical use. We let the clinical question decide, not search trends. A peptide can always move onto our catalog later if a real use case and a safe supply emerge.

Yes, and it is separate from sourcing. We decline peptides whose documented risk outweighs the benefit. This is not about a substance being understudied. It is about a known, serious signal of harm: a peptide linked to significant adverse events, one prone to contamination, or one whose interactions make it hazardous. Investigative reporting has documented adverse events, including deaths, among subjects exposed to several injectable peptides, plus a real risk of immune reactions. When the demonstrated downside is larger than the benefit, we say no.

A peptide is hype when the demand for it is manufactured by marketing rather than grounded in a real clinical use. A compelling mechanism, an influencer protocol, or a viral testimonial is not the same as a definable problem the peptide is meant to solve. We are comfortable with legitimate peptides whose human evidence is still maturing, because there is a real rationale behind them. What we decline is the peptide that exists mainly to be sold.

No. Semaglutide and tirzepatide are not in the PeRx catalog. We are a focused peptide therapy practice, and the body-composition peptides we do offer do a narrower job than a GLP-1: instead of suppressing appetite, they target visceral fat, protect lean mass, and improve how cells handle fuel. We cover that distinction in our guide on [how we approach weight-loss peptides](/blog/how-we-approach-weight-loss-peptides).

Not necessarily, and that is the point. The peptide regulatory landscape has been a shifting gray zone through 2025 and 2026, and legality is not the only question we ask. A peptide can be legal to sell as a research chemical and still fail our standards on sourcing, on having a legitimate medical use, or on risk versus benefit. We frame our decisions around those principles rather than around legality alone. For the broader legal picture, see our guide on [whether peptides are legal in 2026](/blog/are-peptides-legal-2026).

Yes. None of our reasons is permanent by nature. If a peptide gains a legitimate pharmacy-grade source, a defensible medical use, and a risk-benefit profile that holds up, it becomes a candidate. The criteria are fixed; the answer for any given peptide can change as the evidence and supply chain change. What will not change is that the criteria come first and demand comes second.

Because the refusals are the more honest signal. Any clinic can publish a menu. Naming the lines you will not cross, and defending them, is harder and more revealing. We would rather a prospective patient understand the standard than discover later that a service approves everything that pays. A clinic that can articulate what it declines is showing you how it thinks.

Ask what it will not prescribe and why. Confirm that prescriptions are compounded by a licensed pharmacy with a certificate of analysis, that a named provider reviews each intake, and that the practice can explain the clinical reason it carries what it carries. A service that cannot name its limits does not really have standards. The presence of clear, defensible boundaries is one of the better signals of quality.

Related Guides

Continue reading about peptides and protocols that pair well with this guide.

Pinealon, PE-22-28 & Selank Guide (2026)

Three peptides, three layers of brain support. Pinealon restores sleep architecture through pineal gland regulation. PE-22-28 drives neurogenesis by blocking the TREK-1 potassium channel. Selank calms anxiety through GABA modulation without sedation or dependence. Together they rebuild, grow, and protect neural tissue from three independent angles.

18 min readRead

Is CJC-1295/Ipamorelin FDA Approved? (2026 Answer)

The short answer is no. CJC-1295 and Ipamorelin are not FDA-approved drugs. They are compounded medications, prescribed by licensed providers and prepared by regulated pharmacies. Here is what that actually means for you, how it compares to FDA-approved peptides, and why the distinction matters less than most people think.

10 min readRead

Is Sermorelin FDA Approved? Yes Until 2008

Sermorelin has a unique regulatory history. It was FDA-approved in 1997 as Geref Diagnostic for testing pituitary function, and its therapeutic form (Geref) was used for pediatric growth hormone deficiency. Then the manufacturer discontinued it in 2008. Today Sermorelin is only available as a compounded medication. Here is the full story.

10 min readRead

See how we evaluate every request

The peptides on our catalog are the ones left after the standards in this article are applied: a pharmacy-grade source, a legitimate medical use, and a risk-benefit that holds up. Take our short health assessment, and a licensed provider reviews your intake before anything is prescribed. Approved orders ship ready to use, refrigerated, with no mixing on your end.

Get Started

Browse the peptides we do offer Take the assessment

Medical Disclaimer

The information provided on this website, including all articles, guides, and educational content, is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Nothing on this site should be construed as a substitute for professional medical advice from a qualified healthcare provider.

The majority of peptides discussed on this site are not approved by the U.S. Food and Drug Administration (FDA) for the indications described. They are classified as bulk drug substances and are available only through a licensed prescribing provider and compounding pharmacy. All treatments require a valid prescription and provider oversight.

The majority of published research on peptide therapies has been conducted in preclinical (animal) models. While early human data is encouraging, comprehensive clinical trial data remains limited for most peptide compounds. Individual results may vary significantly based on health status, injury type, and other factors. No specific outcomes are guaranteed.

Certain peptides discussed on this site are classified as prohibited substances by the World Anti-Doping Agency (WADA) and are banned by major sports organizations including the NFL, NCAA, UFC, NBA, MLB, NHL, and PGA. If you are subject to anti-doping testing, consult your governing body before considering any peptide therapy.

Statements on this website have not been evaluated by the Food and Drug Administration. Products and therapies discussed are not intended to diagnose, treat, cure, or prevent any disease.

Reviewed by Dr. Cory Mellon, MD · Last reviewed June 2026